Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

1.11
+0.07006.73%
Post-market: 1.09-0.0197-1.77%19:14 EDT
Volume:23.43K
Turnover:25.45K
Market Cap:1.41M
PE:-0.07
High:1.11
Open:1.03
Low:1.03
Close:1.04
Loading ...

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

THOMSON REUTERS
·
20 Nov 2024

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire
·
20 Nov 2024

Pasithea Therapeutics files to sell 3.74M shares of common stock for holders

TIPRANKS
·
08 Oct 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
27 Sep 2024

Top Midday Gainers

MT Newswires Live
·
27 Sep 2024

Shares of Pasithea Therapeutics Rise 77.4% on Positive Early-Stage Data From Cancer Drug

THOMSON REUTERS
·
26 Sep 2024

Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment

Dow Jones
·
26 Sep 2024

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Benzinga
·
26 Sep 2024

BUZZ-Pasithea Therapeutics rises on positive early-stage data from cancer drug

Reuters
·
26 Sep 2024

Top Premarket Gainers

MT Newswires Live
·
26 Sep 2024

Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell

MT Newswires Live
·
26 Sep 2024

BRIEF-Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

Reuters
·
26 Sep 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (Pk), and Preliminary Efficacy Data From Its Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

THOMSON REUTERS
·
26 Sep 2024

Pasithea Therapeutics Corp - No Treatment-Related Adverse Events or Dose-Limiting Toxicities Observed

THOMSON REUTERS
·
26 Sep 2024

Pasithea Therapeutics Corp - Patient With Stage 3 Colon Cancer Achieves Prolonged Stable Disease

THOMSON REUTERS
·
26 Sep 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire
·
26 Sep 2024